| Prev Close | 49.29 |
| Day Low/High | 48.68 / 49.17 |
| 52 Wk Low/High | 37.38 / 51.13 |
| Avg Volume | 6.09M |
| Exchange | NYSE |
| Shares Outstanding | 1.74B |
| Market Cap | 85.64B |
| EPS | 0.90 |
| P/E Ratio | 77.02 |
| Div & Yield | 1.06 (2.20%) |
Latest News
EY's Kerrie MacPherson: "If You Can See It, You Can Be It"
EY's Kerrie MacPherson wants to remove the barriers for young women.
How EY's Kerrie MacPherson Uses Decades of Experience to Help a New Generation of Women Win
EY's Kerrie MacPherson Wants To Pave the Way for future female entrepreneurs.
Weekly Roundup
Markets see volatility as geopolitical tensions rise. We closed out one tech position and initiated another.
Weekly Roundup
Strong earnings and guidance lift markets. We drop a couple of names from the portfolio.
Weekly Roundup
Earnings help boost markets as D.C. isn't counted on for much of anything. Portfolio action (it was a busy week) includes a new position and a downgrade.
Freeport-McMoRan, Apple Hospitality REIT, Abbott Laboratories: 'Mad Money' Lightning Round
Jim Cramer is bullish on Freeport-McMoRan, Apple Hospitality REIT, and Abbott Laboratories.
Reversal of Fortunes: Cramer's 'Mad Money' Recap (Thursday 7/27/17)
Jim Cramer says that when the markets switch abruptly, investors should take the opportunity to go bargain hunting.
If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog
Stock prices are either unfairly dragged down by competitors' earnings news or by Amazon's spread into more businesses, Cramer said.
Weekly Roundup
Earnings help boost markets as D.C. isn't counted on for much of anything. Portfolio action (it was a busy week) includes a new position and a downgrade.
Stocks Are Guilty by Association: Cramer's 'Mad Money' Recap (Thursday 7/20/17)
Jim Cramer says these market rotations are crushing good stocks that don't deserve it.
Abbott CEO: Another Alere-Related Divestiture Coming Soon
Abbott CEO Miles White said on an earnings call the company will make one more asset sale as part of efforts to gain regulatory approval for the Abbott-Alere deal.
Alere, St. Jude Deals in Focus as Abbott Releases Q2 Earnings
Abbott will report second-quarter numbers on Thursday as it completes the Alere deal. $ABT $ALR
Quidel Diversifies With Alere's Triage Assets
The Triage assets are being divested in order to secure antitrust approvals for Abbott Laboratories' purchase of Alere.
Earnings Previews: 7 Names to Report This Week
What we'll be looking for from ABT, NUE, DHR, KEY, SNA, GE and SLB.
Netflix, Microsoft Better Blow Everyone Away With Their Earnings This Week, Or Else
The second-quarter earnings season picks up speed.
Weekly Roundup
The market surged this week as positive earnings and a mellower tone from Janet Yellen cheered bulls.
Abbott, Novartis Show Promise Amid Healthcare Decline, Tiffany Lands Much Needed Boost -ICYMI Thurs.
Here's what you need to know now.
Update on Abbott, TJX and Nucor
A deep dive into 3 of the 10 stocks we highlighted during yesterday's members-only call.
